Photo of Charles J. Dimitroff,  PhD

Charles J. Dimitroff, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-5693
Fax: (617) 525-5571


cdimitroff@rics.bwh.harvard.edu

Charles J. Dimitroff, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Associate Professor, Dermatology, Harvard Medical School
  • Associate Professor, Dermatology, Brigham And Women's Hospital

Research Abstract

My research focuses on understanding the origin and progression of human cancers. This goal is driven from molecular target discovery and target validation approaches. I am currently investigating 1.) how immune cells respond to tumor-derived factors through carbohydrate-dependent mechanisms and 2.) how cell surface carbohydrates on tumor cells can be used to predict tumorigenicity and metastatic progression. We conduct structural and biochemical characterization of the critical carbohydrate determinants on immune/host cells or tumor cells. Results from these studies provide new insights on how tumors become malignant, grow and form distant metastases and how tumors evade host immune responses.

Publications

Powered by Harvard Catalyst
  • Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F, Walley KC, Barthel SR, Opperman MJ, Liang J, Lin JY, Schatton T, Laga AC, Mihm MC, Qureshi AA, Widlund HR, Murphy GF, Dimitroff CJ. Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. J Invest Dermatol 2015. PubMed
  • Burdick MM, Reynolds NM, Martin EW, Hawes JV, Carlson GE, Cuckler CM, Bates MC, Barthel SR, Dimitroff CJ. Isolation and characterization of chimeric human Fc-expressing proteins using protein a membrane adsorbers and a streamlined workflow. 2014. PubMed
  • Dimitroff CJ. Leveraging fluorinated glucosamine action to boost antitumor immunity. Curr Opin Immunol 2012. PubMed
  • Cedeno-Laurent F, Dimitroff CJ. Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj. J. 2012; 29:619-25. PubMed
  • Barthel SR, Hays D, Yazawa EM, Opperman MJ, Walley KC, Nimrichter L, Burdick MM, Gillard BM, Moser MT, Pantel K, Foster BA, Pienta KJ, Dimitroff CJ. Definition of molecular determinants of prostate cancer cell bone extravasation. Cancer Res 2012. PubMed
  • Cedeno-Laurent F, Dimitroff CJ. Evidence of a novel galectin-9-binding membrane glycoprotein ligand on T helper cells. Clin Immunol 2012; 143:6-7. PubMed
  • Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK, Dimitroff CJ. Galectin-1 triggers an immunoregulatory signature in th cells functionally defined by IL-10 expression. J Immunol 2012; 188:3127-37. PubMed
  • Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA, Dimitroff CJ. Galectin-1 inhibits viability, proliferation, and Th1 cytokine production of non-malignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 2012. PubMed
  • Cedeno-Laurent F, Dimitroff CJ. Galectin-1 research in T cell immunity: past, present and future. Clin Immunol 2012; 142:107-16. PubMed
  • Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, Murphy GF, Dimitroff CJ. Metabolic Inhibition of Galectin-1-Binding Carbohydrates Accentuates Antitumor Immunity. J Invest Dermatol 2011. PubMed
  • Barthel SR, Antonopoulos A, Cedeno-Laurent F, Schaffer L, Hernandez G, Patil SA, North SJ, Dell A, Matta KL, Neelamegham S, Haslam SM, Dimitroff CJ. Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J Biol Chem 2011; 286:21717-31. PubMed
  • Cedeno-Laurent F, Barthel SR, Opperman MJ, Lee DM, Clark RA, Dimitroff CJ. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol 2010; 185:4659-72. PubMed
  • Barthel SR, Wiese GK, Cho J, Opperman MJ, Hays DL, Siddiqui J, Pienta KJ, Furie B, Dimitroff CJ. Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A 2009; 106:19491-6. PubMed
  • Wiese G, Barthel SR, Dimitroff CJ. Analysis of physiologic E-selectin-mediated leukocyte rolling on microvascular endothelium. 2009. PubMed
  • Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ. Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology 2008; 18:806-17. PubMed
  • Yamanaka K, Dimitroff CJ, Fuhlbrigge RC, Kakeda M, Kurokawa I, Mizutani H, Kupper TS. Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression. J Allergy Clin Immunol 2007; 121:148-157.e3. PubMed
  • Gainers ME, Descheny L, Barthel SR, Liu L, Wurbel MA, Dimitroff CJ. Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J Immunol 2007; 179:8509-18. PubMed
  • Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007; 11:1473-91. PubMed
  • Alcaide P, King SL, Dimitroff CJ, Lim YC, Fuhlbrigge RC, Luscinskas FW. The 130-kDa glycoform of CD43 functions as an E-selectin ligand for activated Th1 cells in vitro and in delayed-type hypersensitivity reactions in vivo. J Invest Dermatol 2007; 127:1964-72. PubMed
  • Descheny L, Gainers ME, Walcheck B, Dimitroff CJ. Ameliorating skin-homing receptors on malignant T cells with a fluorosugar analog of N-acetylglucosamine: P-selectin ligand is a more sensitive target than E-selectin ligand. J Invest Dermatol 2006; 126:2065-73. PubMed
  • Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res 2005; 65:5750-60. PubMed
  • Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL. Rolling of Human Bone-Metastatic Prostate Tumor Cells on Human Bone Marrow Endothelium under Shear Flow Is Mediated by E-Selectin. Cancer Res 2004; 64:5261-9. PubMed
  • Dimitroff CJ, Kupper TS, Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003; 112:1008-18. PubMed
  • Dimitroff CJ, Bernacki RJ, Sackstein R. Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: implications in modulating lymphocyte migration to skin. Blood 2002; 101:602-10. PubMed
  • Fuhlbrigge RC, King SL, Dimitroff CJ, Kupper TS, Sackstein R. Direct real-time observation of E- and P-selectin-mediated rolling on cutaneous lymphocyte-associated antigen immobilized on Western blots. J Immunol 2002; 168:5645-51. PubMed
  • Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R. A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci U S A 2000; 97:13841-6. PubMed
  • Sackstein R, Dimitroff CJ. A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity. Blood 2000; 96:2765-74. PubMed
Hide